Testing a new combination treatment for advanced lung cancer

Plain-English translation of NCT06512051 on ClinicalTrials.gov ↗ · Source last updated December 2025 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a new medication called SHR-A2102 paired with another drug called Adebrelimab, with or without additional cancer treatments. The study wants to understand if this combination is safe and whether it works well for people with advanced or metastatic non-small cell lung cancer — a type of lung cancer that has spread or cannot be surgically removed.

Current treatments for advanced lung cancer don't work well enough for everyone. Researchers believe combining this new medication with existing therapies might help more patients, so they're testing whether this approach is both safe and effective.

Do you qualify?

You likely qualify if…

you are between 18 and 70 years old
you have been diagnosed with advanced or metastatic non-small cell lung cancer that cannot be surgically removed or treated with radiation alone
you have at least one measurable tumor that doctors can track
you are in good enough health to tolerate the treatment (an ECOG score of 0 or 1)
you are expected to live at least 12 weeks
you have a tumor tissue sample available for testing

You likely don't qualify if…

you have active or symptomatic brain metastases (cancer spread to the brain)
you have had another cancer within the past 5 years (with some exceptions for skin cancers or early cervical/breast cancers)
you have large amounts of fluid around your lungs, heart, or abdomen that cannot be controlled
you have had recent cancer treatment or surgery within the past few weeks
you have a history of a serious lung inflammation condition or currently have signs of one

What participation looks like

You would receive the new medication (SHR-A2102) combined with Adebrelimab, either alone or along with standard chemotherapy or a targeted drug like Bevacizumab. You'll visit the clinic regularly for infusions and blood tests to monitor how well the treatment is working and watch for side effects. The study involves about 248 participants total, and doctors will carefully track your response to see if this combination is safe and effective for your type of lung cancer.

AI-generated summary from trial data · Jun 24, 2026 · Not medical advice

Trial locations(1 site)

China

Chinese People's Liberation Army General Hospital, Beijing, Beijing Municipality